SCHEMBL6979412

SCHEMBL6979412

N#Cc1ccc(CCC(=O)N2CCCc3cc(C(=O)NCCCCc4ccccc4)ccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.49
TP53 P04637 2/20 0.49
CCR3 P51677 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 3/20 0.45
TSHR P16473 2/20 0.45
NPC1 O15118 1/20 0.45
NFKB1 P19838 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
DPP4 P27487 2/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984356 0.94 SMN1; SMN2 (0.53) NAMPTTP53SMN1; SMN2MAPTNPC1
SCHEMBL7085009 0.89 TP53 (0.49) NAMPTTP53SMN1; SMN2MAPTHDAC1
Hydrochloric Acid SCHEMBL6986749 0.87 SMN1; SMN2 (0.46) TP53SMN1; SMN2MAPTTSHRNPC1
SCHEMBL6977738 0.87 TP53 (0.51) TP53SMN1; SMN2MAPTTSHRNPC1
SCHEMBL7964635 0.84 TP53 (0.47) TP53SMN1; SMN2TSHRHDAC1HDAC8
SCHEMBL6977395 0.84 TP53 (0.46) TP53SMN1; SMN2MAPTTSHRNPC1
SCHEMBL6981022 0.83 TP53 (0.51) TP53HDAC1HDAC8HDAC6
SCHEMBL6980215 0.83 TP53 (0.42) NAMPTTP53SMN1; SMN2MAPTNPC1
SCHEMBL7409209 0.82 IDO1 (0.60) TP53SMN1; SMN2MAPTHDAC1HDAC8
SCHEMBL6984354 0.82 PTGER4 (0.49) NAMPTTP53MAPTTSHRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed